The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, in respect of, and assumes no legal liability for, the accuracy, completeness or usefulness of any information disclosed.
This presentation includes market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information.
Forward- looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions.
of the Company’s business plan, the continued growth of the medical cannabis market in the countries in which the Company operates or intends to operate, the Company maintaining “de facto control” over Focus Medical Herbs Ltd.
costs of inputs; crop failures; litigation; currency fluctuations; competition; industry consolidation; failure to meet NASDAQ Capital Market ; delays in the NASDAQ or SEC review of the Company’s listing application or registration of securities with the SEC, including but not limited to delays relating to COVID-19; the Company’s NASDAQ listing application being unsuccessful; and loss of key management and/or employees.
Consequently, the fact that we have provided financial projections to you should not be regarded as a representation by anyone that they will be realized.
States, or to, or for the account or benefit of, “U.S.
Focus Medical, a licensed medical cannabis producer in Israel with whom IMC has exclusive commercial agreements, was the first major Israeli licensed producer to utilize IMC’s intellectual property, know-how and expertise.
Focus Medical, and as such subject to the 5% ownership restriction applicable to Israeli licensed producers.
Under IFRS 10, consolidation occurs when an investor can exercise control over an investee.
of biological assets, realized fair value adjustments on inventory sold in the period, share-based compensation expenses, and revaluation adjustments of financial assets and liabilities measured on a fair value basis.
These non-IFRS financial measures can provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS measures.